Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation. - Peer CJ; Heiss BL; Goldstein DA; Goodell JC; Figg WD; Ratain MJ (Journal of clinical pharmacology, 2022)